Recursion stock jumps on strong Q4 results

Biotech firm beats Wall Street expectations, driven by milestone payment from Roche partnership

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Shares of Recursion Pharmaceuticals (RXRX) surged after the company reported Q4 2025 financial results that significantly exceeded Street forecasts. The strong performance was primarily driven by a milestone payment from the company's partnership with Roche (RHHBY).

Why it matters

Recursion's ability to exceed expectations and generate revenue from its partnerships is a positive sign for the company's growth potential in the competitive biotech industry. The stock jump indicates investor confidence in the company's AI-driven drug development platform and its ability to deliver on key milestones.

The details

For Q4 2025, Recursion reported $35.5 million in revenue, beating Wall Street estimates. This was largely due to a milestone payment from the company's ongoing collaboration with pharmaceutical giant Roche. Recursion is using its proprietary AI and machine learning technology to accelerate drug discovery and development.

  • Recursion reported Q4 2025 financial results on February 25, 2026.

The players

Recursion Pharmaceuticals

An AI-driven biotech company focused on accelerating drug discovery and development.

Roche

A multinational pharmaceutical and diagnostics company that is a partner of Recursion.

Got photos? Submit your photos here. ›

The takeaway

Recursion's ability to generate significant revenue from its partnerships and exceed Wall Street forecasts demonstrates the potential of its AI-powered drug discovery platform. This stock jump signals investor confidence in the company's long-term growth prospects in the competitive biotech industry.